MENU Quick Go

  • HOME
  • About PharmAbcine
  • Board of Directors
Board of Directors

Dr. Jin-San YOO, president and CEO of PharmAbcine, Inc. in South Korea, founded PharmAbcine in 2008 as a spin-off venture company from KRIBB (Korea Research Institute of Biosciences and Biotechnology) with initial funding from Novartis. Before founding PharmAbcine, he served as a head of "The Therapeutic Antibody Center" at KRIBB and director of Therapeutic Antibody Division at LG Life Sciences. Dr. YOO studied microbiology and organic chemistry at Georg-August University Gottingen and received MS and PhD in the field of molecular cell biology at the Max-Planck-Institute for Biophysical Chemistry and was acting as HHMI fellow at Stanford University School of Medicine and as TSRI senior associate at The Scripps Research Institute.
 
Dr. Nancy Chang, is the Chairman and a Senior Managing Director of the Asia team in OrbiMed. Dr. Chang was the Co-Founder, CEO and Chairman of Tanox, Inc. She brings over 25 years of excellence in pioneering scientific research and entrepreneurial success to OrbiMed. Dr. Chang built Tanox from an idea to a substantial publicly-traded company which was acquired by Genentech in August 2007 for $919 Million. Tanox's initial public offering in 2000 was the second largest IPO ever for a biotechnology company at that time. During her career, Dr. Chang has received numerous awards for her leadership, including the Most Respected Woman in Biotechnology (MedAd News, 2005), Global Business Achievement Hall of Fame Governor's Award (2005), Texas Science Hall of Fame (2001), and Houston Entrepreneur of the Year (2000). Dr. Chang serves on the Boards of Directors of the Federal Reserve Bank in Houston, Charles River Laboratories, and she is also a member of the Board of Visitors at M. D. Anderson Cancer Center. Before launching Tanox, Dr. Chang served as Director of Research at Centocor, Inc. She received her Ph.D. in Biological Chemistry from Harvard University.
 
Dr.Jongtae Choi, is CSO at Novartis Korea Ltd. Prior to joining the Novartis Korea in 2007, Dr. Choi had worked as Medical Director at Wyeth Korea Ltd., Organon Korea Ltd., and Eli Lilly Korea Ltd. for about 8 years and served as Director of Family Medicine at several hospitals for 5 years. Dr. Choi studied Medicine and Preventive Medicine for bachelor and master degree, respectively at Yonsei University of Medical College and received Ph.D. with Parasitology from the same university. In addition to medicinal specialty, he had received also MBA degree from Ellis College in New York Institute of Technology in 2005.
 
Dr. Jonathan Wang, is a Senior Managing Director on the Asia Team in OrbiMed. Dr. Wang has nearly 20 years experience in the life sciences field, most recently as General Manager of Burrill & Company's Greater China Group. Prior to Burrill, Dr. Wang worked for WI Harper Group and Walden International, both ranked among the leading global venture capital firms operating in Asia. At WI Harper, Dr. Wang was a Managing Director, overseeing the firm's life sciences activities worldwide. During this time he co-founded Bridge Pharmaceuticals, a pioneering cross-Pacific pharmaceutical R&D services company. Dr. Wang is Co-Founder and former Chairman of The BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. Dr. Wang also earned an M.B.A. from Stanford University.
 
Dr. Eun Chul Huh, is Executive Vice President at Green Cross Corporation, one of the leading pharmaceutical companies in South Korea. Dr. Huh joined the Green Cross in 2006, and is responsible for pursuing collaborations with distinguished companies and institutes in the fields of pharma and biotechnology. Prior to joining the Green Cross he served as Head of R&D Planning at Mogam Biotechnology Research Institute, a non-profit research organization dedicated to the development of vaccines and protein therapeutics. Dr. Huh studied biochemical engineering at Seoul National University and received Ph.D. from Cornell University.